1,2-disubstituted heterocyclic compounds

1. A compound of Formula (I)

or pharmaceutically acceptable salt thereof

wherein:

HET is a heterocyclic ring selected from Formulas A1-A26 and A29-A42 below

and the left most radical is connected to the X group;

X is selected from C 3 -C 8 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 4 -C 7 cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

Y is a bond or a divalent linker group selected from —CH 2 —, —O—, —SO 2 —, —CH 2 O—, —OCH 2 — and —CH 2 CH 2 — with the rightmost radical of the Y group connected to the Z substituent;

Z is optionally substituted heteroaryl;

R 1a is selected from C 1 -C 4 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 4 -C 7 cycloalkylalkyl and optionally substituted C 4 -C 7 alkoxyalkyl;

R 1b is selected from C 1 -C 4 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 4 -C 7 cycloalkylalkyl and optionally substituted C 4 -C 7 alkoxyalkyl;

each R 2 is independently selected from C 1 -C 4 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 4 -C 7 cycloalkylalkyl and optionally substituted C 4 -C 7 alkoxyalkyl, or two R 2 groups taken together form a 3-6 membered cycloalkyl ring;

R 3 and R 4 are independently selected from C 1 -C 4 alkyl, CF 3 , optionally substituted C 3 -C 6 cycloalkyl, or R 3 and R 4 taken together form a 3-6 membered cycloalkyl ring;

R 5 is selected from C 1 -C 4 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 4 -C 7 cycloalkylalkyl and optionally substituted C 4 -C 7 alkoxyalkyl;

R 7 is selected from hydrogen, C 1 -C 4 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 4 -C 7 cycloalkylalkyl and optionally substituted C 4 -C 7 alkoxyalkyl;

n is independently selected from 1 and 2.

2. The compound of claim 1 , wherein HET is a heterocyclic ring of formula selected from the group consisting of A3, A6, A7, A8, A14, A17, A29, A31, A32, A39, and A40;

X is optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl or optionally substituted heteroaryl; and

Y is —CH 2 O— or —OCH 2 —;

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 , wherein Z is an optionally substituted heteroaryl having only 6 ring atoms or an optionally substituted heterobicyclic ring system;

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 2 , wherein Z is an optionally substituted heteroaryl having only 6 ring atoms selected from C and N provided the total number of ring nitrogens is less than or equal to two; said ring is optionally substituted with up to 2 substituents independently selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyloxy, C 4 -C 7 cycloalkylalkyl, cycloalkylalkoxy, halogen, alkylsulfonyl, cyano and nitro;

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 2 , wherein Z is benzimidazolyl, quinolinyl, tetrahydroquinolyl, imidazo[1,2-a]pyridin-2-yl, tetrahydroisoquinolyl, 5-methylpyridin-2-yl, 3,5-dimethylpyridin-2-yl, 6-fluoroquinolyl or isoquinolinyl, each of which is unsubstituted or substituted with up to 3 substituents independently selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyloxy, C 4 -C 7 cycloalkylalkyl, cycloalkylalkoxy, halogen, alkylsulfonyl, cyano and nitro;

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 2 , wherein X is a heterocycloalkyl group having a formula selected form the group consisting of Formulas B1-B16:

wherein R 6 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl;

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 2 , wherein X is phenyl, restricted phenyl, or pyridinyl;

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 2 , wherein X is benzo[d]oxazoyl, benzo[c][1,2,5]oxadiazyl, benzo[c][1,2,5]thiadiazolyl, benzo[d]isoxazolyl, 1H-benzo[d]imidazoyl, benzo[d]thiazoyl, benzo[c]isothiazolyl, benzo[d]isothiazolyl, benzo[c]isoxazolyl, imidazo[1,2-a]pyridinyl or imidazo[1,5-a]pyridinyl;

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 2 , wherein HET is A29;

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 2 , wherein HET is A29;

X is optionally substituted heteroaryl;

Y is —OCH 2 —;

Z is optionally substituted heteroaryl; and

each R 2 is independently C 1 -C 4 alkyl;

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 10 , wherein X is pyridinyl;

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 2 , wherein HET is A29;

X is pyridinyl;

Y is —OCH 2 —;

Z is heteroaryl; and

each R 2 is independently C 1 -C 4 alkyl;

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 2 , wherein HET is A29;

X is pyridinyl;

Y is —OCH 2 —;

Z is heteroaryl; and

each R 2 is methyl;

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 2 , wherein HET is A29;

X is pyridinyl;

Y is —OCH 2 —;

Z is a heterobicyclic ring system containing exactly 9 atoms; and

each R 2 is independently C 1 -C 4 alkyl;

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 2 , wherein HET is A29;

X is pyridinyl;

Y is —OCH 2 —;

Z is a heterobicyclic ring system containing exactly 9 atoms; and

each R 2 is methyl;

or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising the compound of any one of claims 1 - 15 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.